Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (NCT00742924), a non-randomized phase 1 study. The primary outcome is Limiting Toxicity.

2. Clinical Question

3. Trial Design

This was a phase 1 study with non-randomized allocation, no masking, and a single-group design in the registry record. Its registered title identifies feasibility and dose discovery as central aims: zoledronic acid was studied with concurrent chemotherapy in patients with newly diagnosed metastatic osteosarcoma. The Children's Oncology Group was the sponsor. The study began in 2008-08, reached primary completion in 2012-04, and is listed as completed. Registered enrollment was 24.

Four dose-based groups appear in the adverse-event record: chemotherapy with zoledronic acid at 1.2 mg/m2, 2.3 mg/m2, or 3.5 mg/m2, and a group receiving 2.3 mg/m2 after the maximum tolerated dose. The record does not explain how patients were assigned to these groups, whether or how dose decisions depended on earlier patients, or how the maximum tolerated dose was determined. The single-group design label and the presence of several listed groups do not establish a randomized or concurrent-control comparison.

The group descriptions state that treatment during weeks 1-11 included zoledronic acid and chemotherapy, followed by conventional surgery in week 12. They also mention treatment during weeks 13-25, but those regimen descriptions are truncated in the registry record. The primary endpoint's observation window is enrollment through the first 12 weeks of therapy. Consequently, the registered primary question concerns early limiting toxicity rather than a comparison of long-term clinical outcomes.

Other stated outcomes include histologic response in the primary tumor and resected metastases, event-free survival, secondary limiting toxicity, and prognostic value of bone-resorption markers. The registry record does not report outcome analyses for these measures. It also does not report a randomized comparison, a masking procedure, or a control arm receiving chemotherapy without zoledronic acid.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Patients found not to meet the eligibility requirements are by group policy not followed for adverse events or outcome

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Limiting Toxicity, measured over Enrollment through the first 12 weeks of therapy..

The primary endpoint was limiting toxicity, measured as the number of participants with an event. Its timeframe was enrollment through the first 12 weeks of therapy. An event was a CTC AE version 4 grade 3 or 4 non-hematologic toxicity considered possibly, probably, or definitely related to zoledronic acid.

The definition excluded specified events: grade 3 nausea and vomiting controlled with adequate antiemetic prophylaxis; grade 3 transaminase elevation that resolved to grade 2 or lower before the planned post-surgery dose; grade 3 fever or infection; grade 3 or 4 hypocalcemia; grade 3 mucositis; grade 3 fatigue that returned to grade 2 or lower before the planned post-surgery dose; and grade 3 reduced joint range of motion or joint effusion related to the primary tumor. Those exclusions mean that the endpoint is narrower than a count of every severe symptom or laboratory abnormality. Attribution to zoledronic acid was part of the definition, rather than a claim that every event occurring during treatment was caused by the drug.

In general, an early toxicity endpoint is used in a phase 1 study to characterize tolerability and inform dose decisions before focusing on later outcomes. The registered aim of feasibility and dose discovery fits that purpose. However, the registry record does not report the number of participants meeting this primary endpoint, a dose-specific endpoint result, or a summary estimate of limiting toxicity. The safety counts reported elsewhere are not a substitute for that defined endpoint because they do not apply all of its severity, attribution, timing, and exclusion criteria.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

In general, a phase 1 study focuses on feasibility, dose-related safety, and defining a tolerable treatment approach. That broad purpose is consistent with this trial's registered feasibility and dose-discovery title. The specific method used to select or escalate doses is not reported in the registry record. The presence of multiple dose labels is not sufficient to infer a particular escalation design, stopping rule, or decision algorithm.

What a non-randomized, single-group design means

In general, randomization helps balance measured and unmeasured participant characteristics between treatment groups. This study is labeled non-randomized and single-group, so its record does not describe a randomized allocation that would make dose groups exchangeable by design. Four groups are listed in the adverse-event record, but the registry record does not state how participants entered each group. Differences across those groups could reflect dose, participant characteristics, timing, or other factors. Without a suitable randomized comparator and the relevant design details, cross-group contrasts should be treated as descriptive rather than as causal treatment effects.

The trial also has no masking. In general, masking can reduce the influence of treatment knowledge on outcome assessment or reporting. Its absence does not invalidate a toxicity count, but it can matter when judgments about symptoms, severity, or attribution are involved. The registry record does not describe additional procedures used to standardize toxicity assessment across groups.

How to understand the primary endpoint

The endpoint is binary at the participant level: a participant either met the defined limiting-toxicity criteria during the specified window or did not. The unit is participants, not the number of separate toxicity episodes. The definition combines event severity, non-hematologic status, timing, and attribution to zoledronic acid, then excludes several specified event types or circumstances. Each component affects which events count. A broad adverse-event tally therefore cannot be treated as the primary endpoint unless it applies the full registered definition.

In general, adverse-event attribution is a clinical judgment about whether an event may be related to a treatment. Such attribution is not equivalent to proof of causation. Here, the endpoint allows events considered possibly, probably, or definitely related to zoledronic acid, while excluding specified categories. The registry record does not provide participant-level classifications or endpoint counts, so the rate or dose pattern for limiting toxicity cannot be assessed from the posted results.

What a confidence interval would add

In general, a confidence interval describes the range of estimates compatible with the observed data under a statistical model and gives a sense of precision. A point estimate alone can conceal substantial uncertainty when the number of observed participants is limited. This record does not report a primary endpoint estimate or confidence interval, so no precision statement for limiting toxicity can be made. The groups each include 6 participants in the adverse-event summary, but that information does not supply an endpoint estimate or its uncertainty.

General considerations about over-dispersion apply mainly to count outcomes: over-dispersion means that observed variability exceeds what a simple count model expects. It can make standard errors too small if the model fails to account for that extra variation. The primary outcome in this study is registered as a participant count for a binary event, not a rate of recurrent events. The registry record does not report a model, an over-dispersion assessment, or an analysis of repeated toxicity events. Those methods should not be assumed to have been used.

Planning illustrations and observed results

In general, sample-size calculations are planning tools. The stated planning illustration uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is expressed as a stated fraction of an observed effect. For time-to-event outcomes, the planning convention is a total number of events, while other outcomes use participants per arm. These assumptions describe an illustration, not the trial's own design justification. They do not show that the trial had a particular probability of detecting an effect, and they are not observed power.

The record does not provide numerical planning outputs or an effect estimate for the primary endpoint. It also does not report the trial's own sample-size justification. Because the design is registered as single-group and non-randomized, a generic equal-allocation, two-arm illustration should not be read as a description of how this trial was conducted. It cannot replace the missing design rationale or outcome analysis.

Finally, the registry record lists no outcome analyses. Statistical tests, model specifications, adjustment procedures, and confidence intervals for the primary or secondary outcomes are therefore not reported in the registry record. Any detailed inferential interpretation would require results and methods beyond the information recorded.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid", "Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid", "Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid", "Chemotherapy and 2.3 mg/m2 Zoledronic Acid After M")
n      <- c(6, 6, 6, 6)
events <- c(1, 1, 3, 2)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid  6  1  16.7  0.4  64.1  3.0  56.4  3.7  57.9
ARM  Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid  6  1  16.7  0.4  64.1  3.0  56.4  3.7  57.9
ARM  Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid  6  3  50.0  11.8  88.2  18.8  81.2  18.4  81.6
ARM  Chemotherapy and 2.3 mg/m2 Zoledronic Acid After M  6  2  33.3  4.3  77.7  9.7  70.0  9.9  71.0

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists several outcomes beyond limiting toxicity: histologic response in the primary tumor and resected metastases, event-free survival, secondary limiting toxicity, and the prognostic value of bone-resorption markers. When multiple outcomes or comparisons are examined, general statistical practice considers multiplicity because the chance of at least one apparently notable result can increase as more tests are performed. A prespecified hierarchy, adjustment method, or distinction between confirmatory and exploratory outcomes can help explain how such findings should be interpreted. These analysis details are not reported in the registry record.

No outcome analyses are reported, so there are no posted p-values or estimates for which to assess multiplicity adjustments. The record does not state whether interim analyses were planned or conducted, how many comparisons were made, or whether any adjustment was used. Those details should not be inferred from the study's phase or its dose groups.

Missing-data handling is also not reported in the registry record. The record notes that patients found not to meet eligibility requirements were not followed for adverse events or outcomes under group policy. It does not describe the number of such patients, other reasons for missing information, follow-up completeness, or any imputation or sensitivity analyses. Nor does it specify which participants were included in each outcome analysis.

The registered enrollment is 24, but the record does not explain the analysis population for the primary endpoint or secondary outcomes. Without that information and the endpoint results, it is not possible to assess whether exclusions or incomplete follow-up affected the reported findings. The available counts should therefore be understood as the adverse-event summary as recorded, not as a complete account of outcome ascertainment or analysis populations.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The adverse-event summary lists 6 participants at risk for serious adverse events in each of the four groups, with 0 participants affected in every group. For other adverse events, 6 participants are listed as affected in each of the first three groups and 5 in the fourth. These counts describe participants with at least one event in the categories recorded; they are not event totals and do not indicate how many distinct events occurred per participant.

Serious adverse events and limiting toxicity are different classifications. The primary endpoint is restricted to grade 3 or 4 non-hematologic toxicity considered at least possibly related to zoledronic acid, subject to listed exclusions. An event may meet one classification without meeting the other. The adverse-event summary does not provide the information needed to map its counts onto the primary endpoint.

No serious-event terms are listed, and deaths are not reported in the registry record. The absence of a reported serious event in these groups is not evidence that no risk exists; the groups contain only the listed participants and the record does not provide uncertainty estimates. The other-event counts also lack event descriptions, severity, timing, and attribution. They should not be interpreted as a profile of specific toxicities or as proof that an event was caused by a particular treatment component.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a phase 1 study examined zoledronic acid with combination chemotherapy in newly diagnosed metastatic osteosarcoma, with a stated emphasis on feasibility and dose discovery. It defines a primary endpoint for early limiting toxicity and lists several secondary outcomes. The adverse-event summary reports zero serious adverse events among the participants at risk in each listed group, alongside other adverse-event counts. These are descriptive observations, not a complete analysis of the primary endpoint.

The record does not report how many participants experienced limiting toxicity as defined, whether that outcome varied by zoledronic acid dose, or how precise any such estimate would be. It does not report analyses of histologic response, event-free survival, secondary limiting toxicity, or bone-resorption markers. Thus the posted information cannot establish the frequency of the primary endpoint or support a conclusion about efficacy, long-term outcomes, or comparative safety.

Even if outcome counts were available, this non-randomized, single-group design would not provide a randomized control comparison. The listed groups are dose-based, and the group assignment process is not reported. Differences between them would not, on their own, show that dose caused a difference in outcome. A comparison with chemotherapy without zoledronic acid is not reported.

In general, a small early-phase study can contribute information about the observed experience in its participants, but uncertainty and design limitations constrain how broadly findings can be applied. Here, no primary result or interval estimate is posted, and the adverse-event categories do not substitute for those missing results. The most defensible interpretation is therefore limited: the registry records a safety and dose-discovery question, but its posted results are insufficient to answer the primary question or to make a comparative treatment claim.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of why design labels, endpoint definitions, and outcome reporting need to be read together. The record calls the study non-randomized and single-group, yet its adverse-event summary separates participants into four dose-based groups. Those details can coexist, but they do not make the groups randomized controls. The assignment process is not reported, so the group labels alone cannot support causal comparisons.

The primary endpoint is also more specific than a general safety count. It requires a particular severity, toxicity type, attribution, and observation window, while excluding named events or circumstances. The adverse-event summary reports serious and other events but does not provide the information needed to identify participants meeting that endpoint. This illustrates why similarly named safety outcomes should not be treated as interchangeable.

Finally, the registry record demonstrates the difference between a registered question and an answer supported by posted results. It identifies a primary endpoint and secondary outcomes, but reports no outcome analyses. The adverse-event counts offer limited descriptive information, while the principal endpoint result and its precision remain unreported. For biostatisticians and clinical researchers, this distinction is essential: design intent, safety summaries, and inferential findings each answer different questions and should not be substituted for one another.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the available record is that it does not report a result for the primary limiting-toxicity endpoint. The endpoint is defined in detail, but no participant count or estimate is provided. The listed adverse-event counts cannot fill that gap because they do not include the endpoint's full criteria for severity, attribution, timing, and exclusions.

The design is non-randomized and labeled single-group, with no control arm reported. Although four dose-based groups appear in the adverse-event summary, the method of assignment is not described. Without that information, dose-group contrasts cannot be interpreted as controlled treatment comparisons. The record also does not report participant characteristics by group, so comparability cannot be assessed.

Safety information is limited: serious-event counts are given, but serious-event terms are not listed; other-event counts lack descriptions, severity, timing, and causal attribution; and deaths are not reported in the registry record. No uncertainty estimates are reported. These omissions constrain interpretation even of the descriptive counts.

The registry record does not report the sample-size justification, dose-selection procedure, statistical analysis methods, missing-data handling, or analysis populations. It lists several secondary outcomes but no analyses for them. Treatment descriptions for weeks 13-25 are truncated, limiting detailed characterization of the full regimen. The record also notes that patients found not to meet eligibility requirements were not followed for adverse events or outcomes, but does not describe the number of affected patients or other exclusions. Together, these limitations prevent a complete assessment of the study's results and how representative the recorded experience may be.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma — NCT00742924.
• Registry record last updated 2014-07-04; status last verified 2014-06.
• Results first posted 2014-07-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00742924 is a completed phase 1 study sponsored by the Children's Oncology Group. It is registered as non-randomized, unmasked, and single-group, with enrollment of 24. The study examined zoledronic acid given with combination chemotherapy for newly diagnosed metastatic osteosarcoma, with feasibility and dose discovery as stated aims.

The primary endpoint was limiting toxicity during enrollment through the first 12 weeks of therapy. Four zoledronic-acid dose-based groups are listed in the adverse-event summary. Each group lists 6 participants at risk for serious adverse events and 0 affected; other adverse events affected 6 participants in the first three groups and 5 in the fourth. Deaths are not reported in the registry record.

The registry record does not report the primary endpoint result, analyses of the listed secondary outcomes, or statistical analysis details. The adverse-event counts are descriptive and do not establish the frequency of the defined primary endpoint or a causal difference between dose groups.